Identifying High-Risk Patients: Predictors of Progression to CRPC
Автор: GU Oncology Now
Загружено: 2025-09-24
Просмотров: 222
A regional roundtable discussion, moderated by Shilpa Gupta, MD, Cleveland Clinic, examined current and emerging strategies in mHSPC and CRPC, including biomarkers and imaging in treatment selection, evolving use of doublet and triplet therapy, ARPI choices and toxicity considerations, and more. Dr. Gupta was joined by other practitioners at Cleveland Clinic, including Christopher Wee, MD; Abdo Haddad, MD; Adriana Alvarez, MD; Moshe Ornstein, MD; and Brian Haines, MD.
In the third segment, they consider how to identify patients with localized or mHSPC who are at risk of progressing to CRPC, emphasizing factors such as high-volume disease, Gleason score, PSA levels, age, and genomic markers. They also explore treatment strategies for these patients, including the choice of androgen receptor inhibitors, the timing of chemotherapy, and practical considerations such as comorbidities, patient preference, and holistic care.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
